Programs – Publication Format
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action
340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner
Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks
Metagenomi, ALS program, Biogen, Ionis, pharmaceutical industry, drug development, layoffs, market challenges
Congress Must Reauthorize FDA Program for Pediatric Rare Diseases to Save Lives
Pediatric Rare Diseases, FDA Program, Reauthorization, Creating Hope Act, Priority Review Voucher Program
FDA’s Operation Warp Speed for Rare Diseases: First Five Participants Announced
FDA, Operation Warp Speed, Rare Diseases, START Program, Gene Therapies, Neurodegenerative Conditions
Pharmaceutical Companies Prevail in 340B Case as Appeals Court Upholds Discount Restrictions
340B program, drugmakers, discounts, Appeals Court, ruling, healthcare, pharmaceuticals, hospitals, clinics.
Extended Data from Gilead’s PBC Program Strengthens Case Ahead of FDA Ruling
Gilead, PBC Program, FDA Decision, Long-term Data, Primary Biliary Cholangitis